Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$443.89−14.04 (-3.07%)
Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%
Amgen net income
Net income is the profit left for shareholders after every expense, interest and tax.
Amgen's net income for the twelve months ending Sep 30, 2026 was $9.39B, up 34.1% year over year. For fiscal 2025 it was $7.71B, up 88.5% from the year before. Over ten years it grew 1.1% a year on average. The highest annual figure on record is $8.39B in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.71B | +88.5% |
| FY2024 | Dec 31, 2024 | $4.09B | -39.1% |
| FY2023 | Dec 31, 2023 | $6.72B | +2.5% |
| FY2022 | Dec 31, 2022 | $6.55B | +11.2% |
| FY2021 | Dec 31, 2021 | $5.89B | -18.9% |
| FY2020 | Dec 31, 2020 | $7.26B | -7.4% |
| FY2019 | Dec 31, 2019 | $7.84B | -6.6% |
| FY2018 | Dec 31, 2018 | $8.39B | +324.2% |
| FY2017 | Dec 31, 2017 | $1.98B | -74.4% |
| FY2016 | Dec 31, 2016 | $7.72B | +11.3% |
| FY2015 | Dec 31, 2015 | $6.94B | +34.5% |
| FY2014 | Dec 31, 2014 | $5.16B | +1.5% |
| FY2013 | Dec 31, 2013 | $5.08B | +16.9% |
| FY2012 | Dec 31, 2012 | $4.35B | +18.0% |
| FY2011 | Dec 31, 2011 | $3.68B | -20.4% |
| FY2010 | Dec 31, 2010 | $4.63B | +0.5% |
| FY2009 | Dec 31, 2009 | $4.61B | +13.6% |
| FY2008 | Dec 31, 2008 | $4.05B | +31.6% |
| FY2007 | Dec 31, 2007 | $3.08B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.86B | +20.1% |
| Q2 FY2026 | Jun 30, 2026 | $2.38B | +65.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.82B | +5.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.33B | +112.6% |
| Q3 FY2025 | Sep 30, 2025 | $3.22B | +13.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.43B | +92.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.73B | – |
| Q4 FY2024 | Dec 31, 2024 | $627.00M | -18.3% |
| Q3 FY2024 | Sep 30, 2024 | $2.83B | +63.6% |
| Q2 FY2024 | Jun 30, 2024 | $746.00M | -45.9% |
| Q1 FY2024 | Mar 31, 2024 | -$113.00M | -104.0% |
| Q4 FY2023 | Dec 31, 2023 | $767.00M | -52.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.73B | -19.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.38B | +4.7% |
| Q1 FY2023 | Mar 31, 2023 | $2.84B | +92.5% |
| Q4 FY2022 | Dec 31, 2022 | $1.62B | -14.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.14B | +30.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.32B | -18.5% |
| Q1 FY2022 | Mar 31, 2022 | $1.48B | -27.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.90B | +5.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.65B | -9.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.62B | -25.9% |
| Q3 FY2020 | Sep 30, 2020 | $2.02B | +1.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.80B | -6.5% |
| Q1 FY2020 | Mar 31, 2020 | $1.83B | -1.8% |
| Q2 FY2019 | Jun 30, 2019 | $2.18B | -5.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.99B | -13.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.93B | – |
| Q3 FY2018 | Sep 30, 2018 | $1.86B | -8.0% |
| Q2 FY2018 | Jun 30, 2018 | $2.30B | +6.7% |
| Q1 FY2018 | Mar 31, 2018 | $2.31B | +11.6% |
| Q4 FY2017 | Dec 31, 2017 | -$4.26B | -320.4% |
| Q3 FY2017 | Sep 30, 2017 | $2.02B | +0.2% |
| Q2 FY2017 | Jun 30, 2017 | $2.15B | +15.0% |
| Q1 FY2017 | Mar 31, 2017 | $2.07B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.94B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.02B | – |
| Q2 FY2016 | Jun 30, 2016 | $1.87B | – |
See a number that looks wrong?